These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 2870480)
1. Neuroleptics, dopamine, and schizophrenia. Pickar D Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480 [TBL] [Abstract][Full Text] [Related]
2. Perspectives on a time-dependent model of neuroleptic action. Pickar D Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694 [TBL] [Abstract][Full Text] [Related]
3. Dopamine in schizophrenia: a review and reconceptualization. Davis KL; Kahn RS; Ko G; Davidson M Am J Psychiatry; 1991 Nov; 148(11):1474-86. PubMed ID: 1681750 [TBL] [Abstract][Full Text] [Related]
4. Plasma homovanillic acid as an index of central dopaminergic activity: studies in schizophrenic patients. Pickar D; Breier A; Kelsoe J Ann N Y Acad Sci; 1988; 537():339-46. PubMed ID: 2904783 [TBL] [Abstract][Full Text] [Related]
5. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. Pickar D; Labarca R; Doran AR; Wolkowitz OM; Roy A; Breier A; Linnoila M; Paul SM Arch Gen Psychiatry; 1986 Jul; 43(7):669-76. PubMed ID: 3718170 [TBL] [Abstract][Full Text] [Related]
6. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance. Wiesel FA Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610 [TBL] [Abstract][Full Text] [Related]
7. The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients. Konicki PE; Owen RR; Litman RE; Pickar D Life Sci; 1991; 48(14):1411-6. PubMed ID: 2008157 [TBL] [Abstract][Full Text] [Related]
8. Dopamine receptors and the dopamine hypothesis of schizophrenia. Seeman P Synapse; 1987; 1(2):133-52. PubMed ID: 2905529 [TBL] [Abstract][Full Text] [Related]
13. The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis. van Kammen DP Psychol Med; 1991 Nov; 21(4):881-95. PubMed ID: 1685791 [TBL] [Abstract][Full Text] [Related]
14. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Chouinard G; Jones BD Am J Psychiatry; 1980 Jan; 137(1):16-21. PubMed ID: 6101522 [TBL] [Abstract][Full Text] [Related]
15. Persistence of cyclicity of the plasma dopamine metabolite, homovanillic acid, in neuroleptic treated schizophrenic patients. Davila R; Zumarraga M; Andia I; Friedhoff AJ Life Sci; 1989; 44(16):1117-21. PubMed ID: 2565009 [TBL] [Abstract][Full Text] [Related]
16. Molecular attributes of dopamine receptors: new potential for antipsychotic drug development. Hartman DS; Civelli O Ann Med; 1996 Jun; 28(3):211-9. PubMed ID: 8811164 [TBL] [Abstract][Full Text] [Related]
17. Novel pharmacological approaches to the treatment of schizophrenia. Fink-Jensen A Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983 [TBL] [Abstract][Full Text] [Related]
18. The effect of chronic neuroleptic administration on cerebral dopamine receptor function. Rupniak MN; Jenner P; Marsden CD Life Sci; 1983 May; 32(20):2289-311. PubMed ID: 6133203 [TBL] [Abstract][Full Text] [Related]
19. Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia. Pickar D; Litman RE; Konicki PE; Wolkowitz OM; Breier A Mod Probl Pharmacopsychiatry; 1990; 24():124-51. PubMed ID: 1970851 [TBL] [Abstract][Full Text] [Related]
20. The neuropathology of schizophrenia. Bachus SE; Kleinman JE J Clin Psychiatry; 1996; 57 Suppl 11():72-83. PubMed ID: 8941174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]